Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
May 2015

Intranasal Ketamine for MDD
An intranasal application of ketamine could be an easier and more practical means to deliver this rapid-acting agent for patients with major depressive disorder.

Smoking and Erectile Dysfunction
A meta-analysis found a positive dose-response association between both the quantity and duration of smoking and the risk that a patient developed erectile dysfunction.

Statins and Depression Risk
Results from a study of statin use in patients with depression support other evidence that this widely used class of drugs may protect brain health.

A Single Elevated Lithium Level Can Impact Renal Function
In almost 700 lithium-treated patients, a single lithium level greater than 1.0 mmol/L was associated with a significant decrease in estimated glomerular filtration rate (eGFR) for at 3 months.

In Brief
FDA Cautions Against Using Testosterone Products for Low Testosterone Levels Due to Aging; Weight Loss Supplement Contains Hidden Fluoxetine

Antipsychotics in PTSD
Many veterans are treated off-label with antipsychotics for post-traumatic stress disorder (PTSD) despite a lack of evidence for their efficacy.

A Message from Alan J. Gelenberg, M.D.

When I first started writing BTP in the 1970s, it was to bridge the gap between new knowledge in our field and its application to patient care. Over the decades since, the need for this bridge has become even greater. Neuroscience rockets forward. Psychiatrists and other clinicians have a broader array of treatments for patients with mental disorders than we even dreamed of back then. But we have less time to spend with patients and less time to keep up with developments that affect treatment decisions. Our medications, and those prescribed by colleagues in other specialties, are more varied, complex, and prone to interactions. What were formerly crisp boundaries between major psychopharmacologic categories are now murky.

This makes the modern practice of psychiatry challenging—but also fun and promising. With the expanding armamentarium of treatment options comes enhanced ability to alleviate suffering. The mission of BTP remains constant, even while the field grows. We are still here to bridge the gap, to make science applicable and relevant, and to help you in your day-to-day work relieve distress and improve function in patients' lives.